Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2001 3
2002 4
2003 1
2005 1
2006 2
2007 2
2008 3
2010 3
2011 2
2012 4
2013 4
2014 3
2015 2
2016 3
2017 4
2018 1
2019 3
2020 7
2021 4
2022 7
2023 8
2024 5
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
Zhang L, Xie P, Li M, Zhang X, Fei S, Zhao N, Li L, Xie Q, Xu Z, Tang W, Zhu G, Zhu Z, Xu Z, Li J, Zhang C, Boyer JL, Chen W, Cai SY, Pan Q, Chai J. Zhang L, et al. Hepatology. 2025 Mar 1;81(3):774-790. doi: 10.1097/HEP.0000000000001003. Epub 2024 Jul 10. Hepatology. 2025. PMID: 38985995 Free PMC article.
Immunofluorescence revealed that the upregulated SLC35C1 expression mainly occurred in hepatocytes. Liver-specific ablation of Slc35c1 ( Slc35c1 cKO ) significantly aggravated liver injury in mouse models of cholestasis induced by bile duct ligation and 1% ch …
Immunofluorescence revealed that the upregulated SLC35C1 expression mainly occurred in hepatocytes. Liver-specific ablation of Slc …
Down-regulation of SLC35C1 induces colon cancer through over-activating Wnt pathway.
Deng M, Chen Z, Tan J, Liu H. Deng M, et al. J Cell Mol Med. 2020 Mar;24(5):3079-3090. doi: 10.1111/jcmm.14969. Epub 2020 Jan 21. J Cell Mol Med. 2020. PMID: 31961998 Free PMC article.
Meanwhile, in HEK293 cells silencing SLC35C1 activates canonical Wnt pathway, whereas overexpressing SLC35C1 inhibits it. Consistently, the reduction of SLC35C1 in HEK293 cells also elevated the mRNA level of Wnt target genes C-myc, Axin2 and Cyclin D1, as we …
Meanwhile, in HEK293 cells silencing SLC35C1 activates canonical Wnt pathway, whereas overexpressing SLC35C1 inhibits it. Cons …
Systematic pan-cancer analysis identifies SLC35C1 as an immunological and prognostic biomarker.
Xie M, Wang F, Chen B, Wu Z, Chen C, Xu J. Xie M, et al. Sci Rep. 2023 Apr 1;13(1):5331. doi: 10.1038/s41598-023-32375-0. Sci Rep. 2023. PMID: 37005450 Free PMC article.
Based on SLC35C1 expression, a risk factor model was found to predict OS of glioma. In addition, in vitro experiments showed that SLC35C1 knockdown significantly inhibited the proliferation, migration and invasive ability of glioma cells, while SLC35C1 overex …
Based on SLC35C1 expression, a risk factor model was found to predict OS of glioma. In addition, in vitro experiments showed that …
GDP-fucose transporter SLC35C1: a potential regulatory role in cytosolic GDP-fucose and fucosylated glycan synthesis.
Skurska E, Olczak M. Skurska E, et al. FEBS Open Bio. 2025 Aug;15(8):1336-1349. doi: 10.1002/2211-5463.70057. Epub 2025 May 27. FEBS Open Bio. 2025. PMID: 40421778 Free PMC article.
GDP-fucose in mammalian cells could be produced via de novo and salvage pathways in the cytoplasm; the first one is responsible for about 90% of GDP-fucose in the total pool of this nucleotide sugar in the cell. SLC35C1 (C1) is the primary transporter of GDP-fucose to the …
GDP-fucose in mammalian cells could be produced via de novo and salvage pathways in the cytoplasm; the first one is responsible for about 90 …
Defining the mild variant of leukocyte adhesion deficiency type II (SLC35C1-congenital disorder of glycosylation) and response to l-fucose therapy: Insights from two new families and review of the literature.
Tahata S, Raymond K, Quade M, Barnes S, Boyer S, League S, Kumanovics A, Abraham R, Jacob E, Menon P, Morava E. Tahata S, et al. Am J Med Genet A. 2022 Jul;188(7):2005-2018. doi: 10.1002/ajmg.a.62737. Epub 2022 Mar 26. Am J Med Genet A. 2022. PMID: 35338746 Review.
Leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-congenital disorder of glycosylation) is an autosomal recessive disorder characterized by growth and cognitive impairment, peripheral neutrophilia, recurrent infections, and the Bombay blood phenotype. .. …
Leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-congenital disorder of glycosylation) is an autosomal recessive …
Mutations in the SLC35C1 gene, contributing to significant differences in fucosylation patterns, may underlie the diverse phenotypic manifestations observed in leukocyte adhesion deficiency type II patients.
Skurska E, Szulc B, Kreczko K, Olczak M. Skurska E, et al. Int J Biochem Cell Biol. 2024 Aug;173:106602. doi: 10.1016/j.biocel.2024.106602. Epub 2024 Jun 4. Int J Biochem Cell Biol. 2024. PMID: 38843991
In this study, the effect of external fucose was analyzed in SLC35C1 KO cell lines, expressing 11 mutated SLC35C1 proteins, previously discovered in patients with an LAD II diagnosis. ...Thus, for patients diagnosed with LAD II we advocate careful analysis of partic …
In this study, the effect of external fucose was analyzed in SLC35C1 KO cell lines, expressing 11 mutated SLC35C1 proteins, pr …
In vivo evidence for GDP-fucose transport in the absence of transporter SLC35C1 and putative transporter SLC35C2.
Lu L, Varshney S, Yuan Y, Wei HX, Tanwar A, Sundaram S, Nauman M, Haltiwanger RS, Stanley P. Lu L, et al. J Biol Chem. 2023 Dec;299(12):105406. doi: 10.1016/j.jbc.2023.105406. Epub 2023 Oct 28. J Biol Chem. 2023. PMID: 38270391 Free PMC article.
Slc35c1 encodes an antiporter that transports GDP-fucose into the Golgi and returns GMP to the cytoplasm. ...Compound Slc35c1[-/-]Slc35c2[-/-] mutants were indistinguishable in skeletal phenotype from Slc35c1[-/-] embryos and neonates. ...
Slc35c1 encodes an antiporter that transports GDP-fucose into the Golgi and returns GMP to the cytoplasm. ...Compound Slc35c1[ …
Incorporation of fucose into glycans independent of the GDP-fucose transporter SLC35C1 preferentially utilizes salvaged over de novo GDP-fucose.
Skurska E, Szulc B, Maszczak-Seneczko D, Wiktor M, Wiertelak W, Makowiecka A, Olczak M. Skurska E, et al. J Biol Chem. 2022 Aug;298(8):102206. doi: 10.1016/j.jbc.2022.102206. Epub 2022 Jun 27. J Biol Chem. 2022. PMID: 35772493 Free PMC article.
Mutations in the SLC35C1 gene encoding the Golgi GDP-fucose transporter are known to cause leukocyte adhesion deficiency II. However, improvement of fucosylation in leukocyte adhesion deficiency II patients treated with exogenous fucose suggests the existence of an SLC3 …
Mutations in the SLC35C1 gene encoding the Golgi GDP-fucose transporter are known to cause leukocyte adhesion deficiency II. However, …
Triclosan activates c-Jun/miR-218-1-3p/SLC35C1 signaling to regulate cell viability, migration, invasion and inflammatory response of trophoblast cells in vitro.
Huo W, Wang Y, Chen T, Cao T, Zhang Y, Shi Z, Hou S. Huo W, et al. BMC Pregnancy Childbirth. 2022 Jun 6;22(1):470. doi: 10.1186/s12884-022-04791-z. BMC Pregnancy Childbirth. 2022. PMID: 35668364 Free PMC article.
Moreover, solute carrier family 35 member C1 (SLC35C1) was validated as a target gene of miR-218-1-3p, and miR-218-1-3p was sustained to negatively modulate SLC35C1 expression in trophoblast cells. Rescue assays validated the role of TCS/miR-218-1-3p/SLC35C1 …
Moreover, solute carrier family 35 member C1 (SLC35C1) was validated as a target gene of miR-218-1-3p, and miR-218-1-3p was sustained …
Biallelic variants in SLC35C1 as a cause of isolated short stature with intellectual disability.
Knapp KM, Luu R, Baerenfaenger M, Zijlstra F, Wessels HJCT, Jenkins D, Lefeber DJ, Neas K, Bicknell LS. Knapp KM, et al. J Hum Genet. 2020 Sep;65(9):743-750. doi: 10.1038/s10038-020-0764-4. Epub 2020 Apr 21. J Hum Genet. 2020. PMID: 32313197
Variants in SLC35C1 underlie leucocyte adhesion deficiency (LADII) or congenital disorder of glycosylation type 2c (CDGIIc), an autosomal recessive disorder of fucosylation. ...Here we report the use of exome sequencing to identify biallelic variants in SLC35C1 (c.5 …
Variants in SLC35C1 underlie leucocyte adhesion deficiency (LADII) or congenital disorder of glycosylation type 2c (CDGIIc), an autos …
68 results